ResMed's earnings met the Zacks Consensus Estimate in the fiscal second quarter and increased year over year. The company saw increased demand for sleep and respiratory care devices on steady recovery of markets from COVID-19 impacts and a competitor's product recall. The continued robust uptake of ResMed's AirSense 10 and AirSense 11 platforms buoy optimism for the company. In addition, the solid adoption of the AirView for ventilation software solution and ResMed's plans to expand this technology worldwide raise investors' confidence.